Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis

British Journal of Pharmacology

Volumn 168, Issue 2, 2013, Pages 502-517

  Grasselli, G ^a,h   Rossi, S ^a,b   Musella, A ^a   Gentile, A ^a   Loizzo, S ^c   Muzio, L ^e   Di Sanza, C ^a   Errico, F ^f   Musumeci, G ^a   Haji, N ^a   Fresegna, D ^a   Sepman, H ^a   De Chiara, V ^a,b   Furlan, R ^e   Martino, G ^e   Usiello, A ^d,f,g   Mandolesi, G ^a   Centonze, Diego ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Department of Therapeutic Research and Medicines Evaluation   (Italy)

^d EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

excitotoxicity; glutamate; inflammation; multiple sclerosis; neurodegeneration

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; DIZOCILPINE; GLUTAMIC ACID; MOG 3555; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN 35 55; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOFLUORESCENCE; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL ASSESSMENT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXCITATORY POSTSYNAPTIC POTENTIAL; MACROGLIA; MOUSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUADRIPLEGIA; SCORING SYSTEM; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; UPREGULATION;

ANIMALS; DIZOCILPINE MALEATE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GLUTAMIC ACID; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84871575473     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02178.x     Document Type: Article

References (93)

1. Albin RL, Greenamyre JT, (1992). Alternative excitotoxic hypotheses. Neurology 42: 733-738.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition (2011). Br J Pharmacol 164: S1-S324.
3. Arundine M, Tymianski M, (2004). Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 61: 657-668.
4. Audoin B, Zaaraoui W, Reuter F, Rico A, Malikova I, Confort-Gouny S, et al,. (2010). Atrophy mainly affects the limbic system and the deep grey matter at the first stage of multiple sclerosis. J Neurol Neurosurg Psychiatry 81: 690-695.
5. Bakshi R, Benedict RH, Bermel RA, Caruthers SD, Puli SR, Tjoa CW, et al,. (2002). T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 59: 62-68.
6. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, et al,. (2008). Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 2008: 1532-1543.
7. Batista S, Zivadinov R, Hoogs M, Bergsland N, Heininen-Brown M, Dwyer MG, et al,. (2012). Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol 259: 139-146.
8. Bolton C, Paul C, (1997). MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 282: 397-402.
9. Brennan AM, Connor JA, Shuttleworth CW, (2006). NAD(P)H fluorescence transients after synaptic activity in brain slices: predominant role of mitochondrial function. J Cereb Blood Flow Metab 26: 1389-1406.
10. Brennan AM, Connor JA, Shuttleworth CW, (2007). Modulation of the amplitude of NAD(P)H fluorescence transients after synaptic stimulation. J Neurosci Res 85: 3233-3243.
11. Brustovetsky T, Brittain MK, Sheets PL, Cummins TR, Pinelis V, Brustovetsky N, (2011). KB-R7943, an inhibitor of the reverse Na+ /Ca2+ exchanger, blocks N-methyl-D-aspartate receptor and inhibits mitochondrial complex I. Br J Pharmacol 162: 255-270.
12. Calabrese M, Rinaldi F, Grossi P, Mattisi I, Bernardi V, Favaretto A, et al,. (2010). Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis. Mult Scler 16: 1220-1228.
13. Campbell GR, Ziabreva I, Reeve AK, Krishnan KJ, Reynolds R, Howell O, et al,. (2011). Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 69: 481-492.
14. Centonze D, Muzio L, Rossi S, Cavasinni F, De Chiara V, Bergami A, et al,. (2009). Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J Neurosci 29: 3442-3452.
15. Chance B, Cohen P, Jobsis F, Schoener B, (1962). Intracellular oxidation-reduction states in vivo. Science 137: 499-508.
16. Cianfoni A, Niku S, Imbesi SG, (2007). Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 28: 272-277.
17. Compston A, Coles A, (2008). Multiple sclerosis. Lancet 372: 1502-1517.
18. Connor JA, Kreulen DL, Prosser CL, (1976). Relation between oxidative metabolism and slow rhythmic potentials in mammalian intestinal muscle. Proc Natl Acad Sci U S A 73: 4239-4243.
19. Craner MJ, Kataoka Y, Lo AC, Black JA, Baker D, Waxman SG, (2003). Temporal course of upregulation of Na(v)1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis. J Neuropathol Exp Neurol 62: 968-975.
20. Craner MJ, Hains BC, Lo AC, Black JA, Waxman SG, (2004a). Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 127: 294-303.
21. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG, (2004b). Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U S A 101: 8168-8173.
22. Das A, Guyton MK, Matzelle DD, Ray SK, Banik NL, (2008). Time-dependent increases in protease activities for neuronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis. J Neurosci Res 86: 2992-3001.
23. Duguid IC, Smart TG, (2009). Presynaptic NMDA Receptors. In:, Van Dongen AM, (ed.). Biology of the NMDA Receptor. CRC Press: Boca Raton, FL, pp. 313-328.
24. Errico F, Pirro MT, Affuso A, Spinelli P, De Felice M, D'Aniello A, et al,. (2006). A physiological mechanism to regulate d-aspartic acid and NMDA levels in mammals revealed by d-aspartate oxidase deficient mice. Gene 374: 50-57.
25. Errico F, Rossi S, Napolitano F, Catuogno V, Topo E, Fisone G, et al,. (2008). d-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. J Neurosci 28: 10404-10414.
26. Forder JP, Tymianski M, (2009). Postsynaptic mechanisms of excitotoxicity: involvement of postsynaptic density proteins, radicals, and oxidant molecules. Neuroscience 158: 293-300.
27. Giraud SN, Caron CM, Pham-Dinh D, Kitabgi P, Nicot AB, (2010). Estradiol inhibits ongoing autoimmune neuroinflammation and NFkappaB-dependent CCL2 expression in reactive astrocytes. Proc Natl Acad Sci U S A 107: 8416-8421.
28. Gobeske KT, Das S, Bonaguidi MA, Weiss C, Radulovic J, Disterhoft JF, et al,. (2009). BMP signaling mediates effects of exercise on hippocampal neurogenesis and cognition in mice. Plos ONE 4: e7506.
29. Gonsette RE, (2008). Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274: 48-53.
30. Guo F, Maeda Y, Ma J, Delgado M, Sohn J, Miers L, et al,. (2011). Macroglial plasticity and the origins of reactive astroglia in experimental autoimmune encephalomyelitis. J Neurosci 31: 11914-11928.
31. Guo F, Maeda Y, Ko EM, Delgado M, Horiuchi M, Soulika A, et al,. (2012). Disruption of NMDA receptors in oligodendroglial lineage cells does not alter their susceptibility to experimental autoimmune encephalomyelitis or their normal development. J Neurosci 32: 639-645.
32. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, et al,. (2011). Oxidative damage in multiple sclerosis lesions. Brain 134: 1914-1924.
33. Hardin-Pouzet H, Krakowski M, Bourbonniere L, Didier-Bazes M, Tran E, Owens T, (1997). Glutamate metabolism is down-regulated in astrocytes during experimental allergic encephalomyelitis. Glia 20: 79-85.
34. Hayes KC, (2011). Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis. Neuropsychiatr Dis Treat 7: 229-239.
35. Jourdain P, Bergersen LH, Bhaukaurally K, Bezzi P, Santello M, Domercq M, et al,. (2007). Glutamate exocytosis from astrocytes controls synaptic strength. Nat Neurosci 10: 331-339.
36. Kalman B, Laitinen K, Komoly S, (2007). The involvement of mitochondria in the pathogenesis of multiple sclerosis. J Neuroimmunol 188: 1-12.
37. Kambe Y, Nakamichi N, Takarada T, Fukumori R, Nakazato R, Hinoi E, et al,. (2011). A possible pivotal role of mitochondrial free calcium in neurotoxicity mediated by N-methyl-d-aspartate receptors in cultured rat hippocampal neurons. Neurochem Int 59: 10-20.
38. Killestein J, Kalkers NF, Polman CH, (2005). Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci 233: 113-115.
39. Lebel RM, Eissa A, Seres P, Blevins G, Wilman AH, (2012). Quantitative high-field imaging of sub-cortical gray matter in multiple sclerosis. Mult Scler 18: 433-441.
40. Lindblad SS, Mydel P, Hellvard A, Jonsson IM, Bokarewa MI, (2012). The N-methyl-d-aspartic acid receptor antagonist memantine ameliorates and delays the development of arthritis by enhancing regulatory T cells. Neurosignals 20: 61-71.
41. Loitfelder M, Fazekas F, Petrovic K, Fuchs S, Ropele S, Wallner-Blazek M, et al,. (2011). Reorganization in cognitive networks with progression of multiple sclerosis: insights from fMRI. Neurology 76: 526-533.
42. Loizzo S, Pieri M, Ferri A, Carri MT, Zona C, Fortuna A, et al,. (2010). Dynamic NAD(P)H post-synaptic autofluorescence signals for the assessment of mitochondrial function in a neurodegenerative disease: monitoring the primary motor cortex of G93A mice, an amyotrophic lateral sclerosis model. Mitochondrion 10: 108-114.
43. MacDermott AB, Role LW, Siegelbaum SA, (1999). Presynaptic ionotropic receptors and the control of transmitter release. Annu Rev Neurosci 22: 443-485.
44. Mahad D, Ziabreva I, Lassmann H, Turnbull D, (2008). Mitochondrial defects in acute multiple sclerosis lesions. Brain 131: 1722-1735.
45. Manabe T, Wyllie DJ, Perkel DJ, Nicoll RA, (1993). Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J Neurophysiol 70: 1451-1459.
46. Matute C, (2010). Calcium dyshomeostasis in white matter pathology. Cell Calcium 47: 150-157.
47. Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV, (2001). The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 24: 224-230.
48. Mayevsky A, Nioka S, Chance B, (1988). Fiber optic surface fluorometry/reflectometry and 31-p-NMR for monitoring the intracellular energy state in vivo. Adv Exp Med Biol 222: 365-374.
49. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reportingexperiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
50. Miglio G, Varsaldi F, Lombardi G, (2005). Human T lymphocytes express N-methyl-D-aspartate receptors functionally active in controlling T cell activation. Biochem Biophys Res Commun 338: 1875-1883.
51. Mu Y, Otsuka T, Horton AC, Scott DB, Ehlers MD, (2003). Activity-dependent mRNA splicing controls ER export and synaptic delivery of NMDA receptors. Neuron 40: 581-594.
52. Musumeci G, Grasselli G, Rossi S, De Chiara V, Musella A, Motta C, et al,. (2011). Transient receptor potential vanilloid 1 channels modulate the synaptic effects of TNF-α and of IL-1β in experimental autoimmune encephalomyelitis. Neurobiol Dis 43: 669-677.
53. Newcombe J, Uddin A, Dove R, Patel B, Turski L, Nishizawa Y, et al,. (2008). Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 18: 52-61.
54. Nicoll RA, Malenka RC, (1999). Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann N Y Acad Sci 868: 515-525.
55. Ohgoh M, Hanada T, Smith T, Hashimoto T, Ueno M, Yamanishi Y, et al,. (2002). Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J Neuroimmunol 125: 170-178.
56. Olechowski CJ, Parmar A, Miller B, Stephan J, Tenorio G, Tran K, et al,. (2010). A diminished response to formalin stimulation reveals a role for the glutamate transporters in the altered pain sensitivity of mice with experimental autoimmune encephalomyelitis (EAE). Pain 149: 565-572.
57. Olney JW, (1969). Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164: 719-721.
58. Pampliega O, Domercq M, Soria FN, Villoslada P, Rodriguez-Antiguedad A, Matute C, (2011). Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation 8: 63.
59. Parri R, Crunelli V, (2007). Astrocytes target presynaptic NMDA receptors to give synapses a boost. Nat Neurosci 10: 271-273.
60. Paul C, Bolton C, (2002). Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine. J Pharmacol Exp Ther 302: 50-57.
61. Pitt D, Werner P, Raine CS, (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67-70.
62. Pitt D, Nagelmeier IE, Wilson HC, Raine CS, (2003). Glutamate uptake by oligodendrocytes: implications for excitotoxicity in multiple sclerosis. Neurology 61: 1113-1120.
63. Plaut GS, (1987). Effectiveness of amantadine in reducing relapses in multiple sclerosis. J R Soc Med 80: 91-93.
64. Pohl HB, Porcheri C, Mueggler T, Bachmann LC, Martino G, Riethmacher D, et al,. (2011). Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J Neurosci 31: 1069-1080.
65. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J, (2006). Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem 281: 31950-31962.
66. Reijerkerk A, Kooij G, van der Pol SM, Leyen T, Lakeman K, Hof B, et al,. (2010). The NR1 subunit of NMDA receptor regulates monocyte transmigration through the brain endothelial cell barrier. J Neurochem 113: 447-453.
67. Rosenstock TR, Bertoncini CR, Teles AV, Hirata H, Fernandes MJ, Smaili SS, (2010). Glutamate-induced alterations in Ca2+ signaling are modulated by mitochondrial Ca2+ handling capacity in brain slices of R6/1 transgenic mice. Eur J Neurosci 32: 60-70.
68. Rossi S, De Chiara V, Furlan R, Musella A, Cavasinni F, Muzio L, et al,. (2010). Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 24: 1379-1385.
69. Rossi S, Muzio L, De Chiara V, Grasselli G, Musella A, Musumeci G, et al,. (2011). Impaired striatal GABA transmission in experimental autoimmune encephalomyelitis. Brain Behav Immun 25: 947-956.
70. Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F, et al,. (2012). Interleukin-1β causes synaptic hyperexcitability in multiple sclerosis. Ann Neurol 71: 76-83.
71. Saab CY, Craner MJ, Kataoka Y, Waxman SG, (2004). Abnormal Purkinje cell activity in vivo in experimental allergic encephalomyelitis. Exp Brain Res 158: 1-8.
72. Sajad M, Zargan J, Sharma J, Chawla R, Arora R, Umar S, et al,. (2011). Increased spontaneous apoptosis of rat primary neurospheres in vitro after experimental autoimmune encephalomyelitis. Neurochem Res 36: 1017-1026.
73. Sarchielli P, Greco L, Floridi A, Gallai V, (2003). Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 60: 1082-1088.
74. Schuchmann S, Kovacs R, Kann O, Heinemann U, Buchheim K, (2001). Monitoring NAD(P)H autofluorescence to assess mitochondrial metabolic functions in rat hippocampal-entorhinal cortex slices. Brain Res Brain Res Protoc 7: 267-276.
75. Shuttleworth CW, Brennan AM, Connor JA, (2003). NAD(P)H fluorescence imaging of postsynaptic neuronal activation in murine hippocampal slices. J Neurosci 23: 3196-3208.
76. Smith T, Groom A, Zhu B, Turski L, (2000). Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6: 62-66.
77. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D, (2005). Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128: 1016-1025.
78. Stanika RI, Winters CA, Pivovarova NB, Andrews SB, (2010). Differential NMDA receptor-dependent calcium loading and mitochondrial dysfunction in CA1 vs. CA3 hippocampal neurons. Neurobiol Dis 37: 403-411.
79. Starke K, Gothert M, Kilbinger H, (1989). Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69: 864-989.
80. Stover JF, Lowitzsch K, Kempski OS, (1997). Cerebrospinal fluid hypoxanthine, xanthine and uric acid levels may reflect glutamate-mediated excitotoxicity in different neurological diseases. Neurosci Lett 238: 25-28.
81. Tao G, Datta S, He R, Nelson F, Wolinsky JS, Narayana PA, (2009). Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry. J Neurol Sci 282: 39-46.
82. Thomson AM, (2000). Facilitation, augmentation and potentiation at central synapses. Trends Neurosci 23: 305-312.
83. Vallejo-Illarramendi A, Domercq M, Perez-Cerda F, Ravid R, Matute C, (2006). Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 21: 154-164.
84. Vercellino M, Merola A, Piacentino C, Votta B, Capello E, Mancardi GL, et al,. (2007). Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 66: 732-739.
85. Wallström E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T, (1996). Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 137: 89-96.
86. Waxman SG, (2005). Cerebellar dysfunction in multiple sclerosis: evidence for an acquired channelopathy. Prog Brain Res 148: 353-365.
87. Werner P, Pitt D, Raine CS, (2001). Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2: 169-180.
88. Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J, (2010). Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 10: 411-418.
89. Xin WK, Kwan CL, Zhao XH, Xu J, Ellen RP, McCulloch CA, et al,. (2005). A functional interaction of sodium and calcium in the regulation of NMDA receptor activity by remote NMDA receptors. J Neurosci 25: 139-148.
90. Yang J, Woodhall GL, Jones RS, (2006). Tonic facilitation of glutamate release by presynaptic NR2B-containing NMDA receptors is increased in the entorhinal cortex of chronically epileptic rats. J Neurosci 26: 406-410.
91. Yashiro K, Philpot BD, (2008). Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 55: 1081-1094.
92. Yu XM, (2006). The role of intracellular sodium in the regulation of NMDA-receptor-mediated channel activity and toxicity. Mol Neurobiol 33: 63-80.
93. Ziehn MO, Avedisian AA, Tiwari-Woodruff S, Voskuhl RR, (2010). Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 90: 774-786.